SAN MATEO, Calif., May 22, 2012 (GLOBE NEWSWIRE) -- Epocrates, Inc. (Nasdaq:EPOC) continues its market leadership in the digital medical category, according to the recently released Manhattan Research Taking the Pulse® U.S. 2012 annual study of physicians' technology adoption and behavior.
Relevant findings from the Taking the Pulse U.S. study include:
- Epocrates is the number one medical app among physicians in terms of reach, both on smartphones and tablets.
- Among physicians using the Epocrates app on a smartphone, more than half use it daily.
- Drug references are the top digital resources accessed by physicians during patient consultations on a smartphone.
"Epocrates is the first place many physicians turn for concise, trusted information, as demonstrated by these findings," said Andy Hurd, president and chief executive officer for Epocrates. "We are committed to continuing to deliver the clinical content and tools they need in the exact time, place and format they want to access it."
Taking the Pulse U.S. 2012 is a physician research study and advisory service fielded annually by Manhattan Research focused on understanding technology adoption and current and future use among U.S. practicing physicians. The survey was conducted among a randomized sample of 3,015 U.S. practicing physicians using an online survey fielded in March and April 2012.
About Epocrates, Inc.
Epocrates, Inc. (Nasdaq:EPOC) is a leading physician platform for clinical content, practice tools and health industry engagement at the point of care. The Epocrates network consists of more than one million healthcare professionals, including 50 percent of U.S. physicians, who routinely use its solutions and services. Epocrates' portfolio includes top-ranked medical apps, such as the industry's #1 medical app among U.S. physicians, and valuable manufacturer resources. Through these intuitive and reliable resources, Epocrates supports clinical decisions, helps improve physician workflow and impacts patient outcomes. For more information, please visit www.epocrates.com/company.
Epocrates is a trademark of Epocrates, Inc., registered in the U.S. and other countries.
The Epocrates, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10943
Certain statements contained in this press release are forward-looking statements intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. The forward-looking statements include uncertainties and risks including, among others: the inability to retain and expand the Epocrates physician network at the rate expected; unexpected delays in delivering new products; lack of market acceptance of new products; the inability to maintain product quality and brand credibility; the inability to keep up with the technological advances within the marketplace and by competitors; the inability to realize estimates and guidance made by management with respect to Epocrates' financial results; and other factors, including general economic conditions and regulatory developments not within Epocrates' control. The factors discussed herein and expressed from time to time in Epocrates' filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release, and except as required by law, Epocrates undertakes no obligation to publicly update its forward-looking statements to reflect subsequent events or circumstances. You should review the Epocrates' filings, especially the risk factors contained in its most recent filings with the Securities and Exchange Commission on Form 10-K and Form 10-Q.